trending Market Intelligence /marketintelligence/en/news-insights/trending/CCa7sLl4SQF4t4gtWgULQg2 content esgSubNav
In This List

Luminex completes acquisition of Merck KGaA's cell analysis unit in $75M deal

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Luminex completes acquisition of Merck KGaA's cell analysis unit in $75M deal

Luminex Corp. has completed the acquisition of Merck KGaA's cell analysis equipment provider MilliporeSigma in a $75 million cash, stock and asset deal.

The acquisition expands the Austin, Texas-based company's footprint in life science research and broadens its existing offering of flow-based detection systems. The portfolio includes flow cytometry products sold under the brand names Amnis, for cell-based analysis, and Guava, which are high-performance systems based on microcapillary technologies.

Luminex expects the acquisition to contribute $40 million to $50 million toward its 2019 revenues.

Cantor Fitzgerald & Co. acted as financial adviser and Smith Gambrell & Russell LLP served as legal counsel to Luminex.